Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Last trade$25.12
Day change-$2.00 (-7.37%)
Day range$25.00 – $27.82
Volume262,215
Market cap$1.09B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.09B
Price / earnings
—
Price / book
3.67×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.86×
Profitability
Earnings per share
-$2.37
Return on assets
-29.15%
Return on equity
-32.1%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.05×
Current ratio
18.12×
Quick ratio
18.12×
Cash ratio
17.9×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$79.68M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANRO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$9.06M
$7.02M
$6.84M
$5.06M
$4.43M
$5.56M
$5.7M
$6.2M
Research and development
$18.16M
$22.11M
$20.29M
$12M
$10.53M
$13.12M
$9.97M
$10.8M
Total operating expenses
$27.23M
$29.13M
$27.14M
$17.06M
$14.95M
$18.68M
$15.68M
$17M
Operating income
-$27.23M
-$29.13M
-$27.14M
-$17.06M
-$14.95M
-$18.68M
-$15.68M
-$17M
Interest expense
-$463K
-$491K
-$545K
-$575K
-$650K
-$646K
-$598K
-$333K
Income before taxes
-$25.12M
-$27.64M
-$26.24M
-$16.18M
-$14.18M
-$17.71M
-$15.17M
-$15.2M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$25.12M
-$27.64M
-$26.24M
-$16.18M
-$14.18M
-$17.71M
-$15.17M
-$15.2M
Net income attributable to common shareholders
-$25.12M
-$27.64M
-$26.24M
-$16.18M
-$14.18M
-$17.71M
-$15.17M
-$15.2M
EBITDA
-$27.04M
-$28.95M
-$26.95M
-$16.9M
-$14.79M
-$18.51M
-$15.51M
-$16.83M
Basic earnings per share
-$0.54
-$0.65
-$0.80
-$0.47
-$0.52
-$0.65
-$0.56
-$0.56
Diluted earnings per share
-$0.54
-$0.65
-$0.80
-$0.47
-$0.52
-$0.65
-$0.56
-$0.56
Recent news
Company coverage with links to the original publishers.
UnitedHealth Group (UNH) has gained 24.8% year-to-date, outperforming the broader Medical sector's 9% average gain. The company holds a Zacks Rank #2 (Buy) with improved analyst sentiment, as consensus earnings estimates have risen 4.6% in the past quarter. However, UNH slightly underperforms its Medical-HMOs industry group, which has averaged 28.6% gains. Alto Neuroscience (ANRO) is also highlighted as an outperformer with 52.4% year-to-date returns.
Alto Neuroscience, Inc. (ANRO) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and positive earnings estimate revisions.
Alto Neuroscience (ANRO) has gained 34.6% over the past four weeks and Wall Street analysts predict a potential 29.4% upside with a mean price target of $38.22. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, with four estimates moving higher over the last 30 days and a 7% increase in consensus estimates. However, the article cautions that price targets should not be the sole basis for investment decisions.
Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth.
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.